VDC Platform
Multiple Solid Tumors
Key Facts
About Aura Biosciences
Aura Biosciences is leveraging its proprietary Virus-Like Drug Conjugate (VDC) platform to develop targeted therapies for solid tumors, with an initial focus on ocular and urologic oncology. The company's lead program targets choroidal melanoma, a rare cancer where current radiotherapy treatments often lead to severe vision loss and poor long-term survival. Aura's approach aims to transform cancer treatment by enabling precise tumor targeting while sparing healthy tissue, potentially offering a vision-preserving alternative to existing standards of care.
View full company profileAbout Aura Biosciences
Aura Biosciences is leveraging its proprietary Virus-Like Drug Conjugate (VDC) platform to develop targeted therapies for solid tumors, with an initial focus on ocular and urologic oncology. The company's lead program targets choroidal melanoma, a rare cancer where current radiotherapy treatments often lead to severe vision loss and poor long-term survival. Aura's approach aims to transform cancer treatment by enabling precise tumor targeting while sparing healthy tissue, potentially offering a vision-preserving alternative to existing standards of care.
View full company profileTherapeutic Areas
Other Multiple Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| BAY 1817080 | Bayer | Phase 1 |
| Zanzalintinib + nivolumab | Exelixis | Phase 1b/2 |
| Zanzalintinib + atezolizumab | Exelixis | Phase 1b/2 |
| XL309 | Exelixis | Phase 1 |
| XB010 | Exelixis | Phase 1 |
| XB628 | Exelixis | Phase 1 |
| XB371 | Exelixis | Phase 1 |
| ADU-1805 | Exelixis | Phase 1 |
| Multiple Preclinical Programs | Perspective Therapeutics | Preclinical |
| Pre-Targeting Platform | Perspective Therapeutics | Preclinical |
| MGC026 | MacroGenics | Phase 1 |
| MGC028 | MacroGenics | Phase 1 |